ShireÀÀÁÊBaxalta ¯A¸ê300»õ
§ë¸êªÌ¬Ý²H Baxalta¦¬¥«»ù»·»¹¦¬ÁÊ»ù
¡i©ú³ø±M°T¡j·Rº¸Äõ»sÃĤ½¥qShire(¥N¸¹SHPG)¬Q¤Ñ«Å¥¬¡Ap¹º¥H¥þ´«ªÑ¤è¦¡¡A¦¬ÁÊè¦b¤W¤ë±qBaxter International(¥N¸¹BAX)¤À©î¤W¥«ªºBaxalta(¥N¸¹BXLT)¡A¯A¤Î300»õ¬ü¤¸¡A¥H¥[±j¦b¥þ²y¨u¦³¯e¯f¥«³õªº»â¾É¦a¦ì¡C
³o¬OShire¨â¤Ñ¤º«Å¥¬ªº²Ä¤G©v¦¬ÁÊp¹º¡C©P¤@¸Ó¤½¥q«Å¥¬¡A¦P·N¥H3»õ¬ü¤¸²{ª÷¡A¦¬Áʨp¤H¾Ö¦³ªºForesight Biotherapeutics¡A¥HÀò±o«áªÌ§Y±N¬ãµo¦¨¥\ªº¬õ²´¯g·sÃÄ¡C
©P¤@è¥H3»õÁʲ´ÃĤ½¥qForesight
ShireºÙ¡A¥Ñ©óBaxaltaºÞ²z¼h©Úµ´¥¦ªº¦¬ÁÊ«Øij¡A©Ò¥H¤½¶}«Øij¡AÅýBaxaltaªÑªF¨M©w¡C
Shire³zÅS¡A¨CªÑBaxalta¥i´«0.1687ªÑShireªº¬ü°ê¹w°UÃÒ¨é(ADS)¡A®Ú¾Ú©P¤@Âù¤èªºªÑ»ù¡A¥¦ªº´«ªÑ«Øijµ¹¤©¨CªÑBaxaltaªº¦ôȬ°45.23¬ü¤¸¡A¦³·¸»ù37¢H¡C
¦¬ÁÊ»ù$45.23 ¦¬¥«»ù¥u±o$37.1
®ø®§¥OBaxaltaªÑ»ù‘C¤É¡A³Ì¦h¤É18.2¢H¦Ü39.19¬ü¤¸¡A¦¬³ø37.1¬ü¤¸¡A¤´¤É3.95¬ü¤¸©Î11.92¢H¡F¥Ñ©ó¦¬¥«»ù»·§C©óShire«Øijªº¦¬ÁÊ»ù¡A·N¨ý§ë¸êªÌ¹w´ÁShire¦¬ÁÊ¥¢±Ñ¡C
ShireªºADS¦b¯Ã¬ù¦¬³ø253.6¬ü¤¸¡A¶^14.48¬ü¤¸©Î5.4¢H¡C
BaxaltaÁ`³¡³]¦b¥ì§Q¿Õ¦{¡A¦³1.6¸U¦Wû¤u¡Aµo®i¨u¦³¦å²G¯e¯f¡BÀù¯g¤Î§K¬Ì¨t²Î¯e¯fªº¥Íª«¬ì§ÞÀøªk¡C¥h¦~¾P°â¦¬¤J¬°60»õ¬ü¤¸¡C
¤ÀªRû«ü¥X¡AShire¦pÁʱoBaxalta¡A«K¥i¥H¸É¨¬¥»¨¨³³t¼W¥[ªº¨u¦³¯e¯f©ù¶QÃĪ«²Õ¦X¡C¤£¹L¡A¤£¯à«OÃÒShire¯à¦¨¥\¦¬ÁÊ¡C
»sÃÄ·~¼Ä·N¦¬Áʦ¨¥\²v§C
Leerink¤ÀªRûJason Gerberry»¡¡G¡uShire¥i¯à¶·n¶i¦æ¼Ä·N¦¬ÁÊ¡A¦Ó»sÃÄ·~¤ºªº¼Ä·N¦¬Áʦ¨¥\²v«Ü§C¡C¡v
Shireªí¥Ü¡A¦p¦¨¥\¦¬ÁÊBaxalta¡A±N³Ð«ØµL¥i¤Ç¼Äªº¨u¦³¯e¯f»sÃÄ°Ó¡A¹wp¨ì2020¦~³o¤è±¨C¦~¾P°â¦¬¤J¹F200»õ¬ü¤¸¡A¦Ó¥B¨C¦~¾P°â±N¦³Âù¦ì¼Æ¦r¼Wªø²v¡C
¥þ²yÂåÀø«O°··~¥h¦~ªìÃzµo¨ÖÁʼé¡A¨ÖÁʬ¡°Ê¤]±q¤j«¬»sÃÄ°Ó¦¬Áʸû¤p¦P·~¡A½¯©µ¦Ü¥é»sÃÄ°Ó¤§¶¡¾ã¦X¡A¥H¦ÜÂåÀø«OÀI°Ó¤§¶¡ªº¨ÖÁÊ¡C